Multiple AI-driven initiatives are reshaping biotech research and diagnostics. Xaira Therapeutics has released an expansive Perturb-seq dataset to accelerate virtual cell modeling and AI drug discovery. New computational tools, including TACIT for multiplexed imaging data and moPepGen for identifying non-canonical protein variants, enhance biomarker discovery and disease analysis. Partnerships like Agenus with Noetik leverage AI foundation models to uncover immuno-oncology biomarkers. These advances exemplify the rapid integration of AI to streamline drug development and improve precision medicine.